Citi raised the firm’s price target on Baxter to $40 from $38 and keeps a Neutral rating on the shares. The firm wonders if the recent rally in medical technology shares can hold heading into the Q3 reports. Citi enters earnings season “cautious,” saying Q3 is historically the toughest quarter in MedTech as it brings scrutiny over the 2025 setup and commentary on next year’s numbers “could be a governor of price action in the near-term.” The firm maintains its top picks on Boston Scientific (BSX), GE HealthCare (GEHC) and Insulet (PODD).
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX:
- Baxter International Responds to Hurricane Impact on Facility
- Baxter financial impact from Helene ‘not a big deal,’ says Morgan Stanley
- Baxter says North Cove, NC facility affected by Hurricane Helene
- Baxter International Welcomes Jeffrey A. Craig to Board
- Election 2024: Where To Put Your Money Ahead of the Vote